Skip to main content

Table 1 Numbers of patients screened and baseline characteristics of patients enrolled in the therapeutic efficacy study at four sentinel sites in 2016

From: Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

Variable Kibaha Mkuzi Mlimba Ujiji Overall
Screened 158 177 295 333 963
Enrolled (%) 80 (50.6) 88 (49.7) 88 (30.3) 88 (26.4) 344 (35.7)
Age in years, mean (SD)a 6.5 (2.7) 5.7 (2.8) 3.4 (2.3) 4.6 (2.9) 5.0 (2.9)
Children < five years of age, n (%)† 29 (36.3) 36 (40.9) 66 (75.0) 58 (65.9) 189 (54.9)
Sex (male), n (%) 46 (57.5%) 49 (55.7%) 49 (55.7%) 52 (59.1%) 196 (57.0)
Weight (kg), mean (SD)b 19.1 (5.6) 17.4 (5.0) 13.1 (4.3) 14.9 (5.1) 16.1 (5.5)
Height in cm, median (IQR)c 114.0 (98.5, 128.3) 111.0 (92.1, 121.0) 85.5 (77.0, 99.8) 97.0 (86.0, 111.8) 100.0 (85.0, 117.8)
Temperature in  °C, mean (SD) 37.8 (1.4) 37.7 (1.1) 37.6 (1.3) 37.7 (1.4) 37.7 (1.3)
Parasitaemia* (95% CI)a 9403 (5901–14,984) 32,357 (23,393–44,756) 27,720 (20,706–37,108) 41,106 (30,356–55,664) 24,806 (20,701–29,726)
  1. °C: degree Celsius; parasitaemia*: geometric mean parasite density (asexual parasites/µl); IQR: interquartile range; n: number of patients; SD: standard deviation; 95% CI : 95% confidence interval. † p < 0.001; athe mean was significantly different between all paired comparison of the sites (p ≤ <0.031) except for Kibaha vs Mkuzi (p = 0.300); bthe mean weight was significantly different between all paired comparison of the sites (p ≤ <0.005) except for Kibaha vs Mkuzi (p = 0.200), and Mlimba vs Ujiji (p = 0.120); cthe mean height was significantly different between all paired comparison of the sites (p < 0.001) except for Kibaha vs Mkuzi (p = 0.138), and Mkuzi vs Ujiji (p = 0.068)